# HepG2 cells stimulated by THP-1-conditioned medium: a potential in vitro model of systemic inflammation–induced hepatic alterations

**Authors:** Veronika Vyletelová, Marek Bohunčák, Jana Hricovíniová, Gabriela Greifová, Peter Vavrinec, Jakub Krivý, Dimitris Kardassis, Ľudmila Pašková

PMC · DOI: 10.1007/s11033-026-11641-0 · 2026-03-06

## TL;DR

This study creates an in vitro model using HepG2 cells and THP-1-conditioned medium to study how systemic inflammation affects liver metabolism and lipoprotein changes.

## Contribution

A novel in vitro model is developed to study inflammation-induced hepatic metabolic changes under conditions mimicking systemic inflammation.

## Key findings

- Short-term exposure to THP-1-conditioned medium altered inflammatory gene and transcription factor mRNA expression in HepG2 cells.
- Lipoprotein-associated gene expression was significantly modified at different time points following exposure.
- The model showed no effect on HepG2 cell viability after 24 hours of exposure.

## Abstract

Chronic inflammatory diseases are associated with qualitative and quantitative changes in lipid and lipoprotein metabolism, including high density lipoproteins (HDLs), increasing patients´ susceptibility to atherosclerosis and cardiovascular mortality. Given the liver’s central role in lipoprotein metabolism and systemic inflammation, we aimed to develop and investigate an in vitro model of inflammation-induced hepatic metabolic changes.

To better approximate in vivo conditions, where systemic inflammation exposes the liver to a complex environment rich in cytokines and inflammatory mediators, we exposed human hepatocarcinoma HepG2 cells to conditioned media (CM) from THP-1-derived macrophages using phorbol-12-myristate-13-acetate (PMA) and lipopolysaccharide (LPS). The effect of CM on mRNA expression in HepG2 was tested by quantitative real-time PCR or protein expression by Western blot analysis. Even short-term exposure to CM (2–4 h) led to a significant change in the mRNA expression of inflammatory genes and several transcription factors (e.g., TNF-α, NF-κB, PPARα, and LRH-1). This change was accompanied by alternations in the expression of lipoprotein-associated genes at different time points (e.g. SAA, LDLr, ApoA1, ABCA1, PON1, and PCSK9). After 24 h of exposure, no effect on HepG2 viability was observed.

In our model, we observed several significant inflammation-induced changes in hepatic lipoprotein metabolism, making it a valuable in vitro system for further mechanistic studies.

The online version contains supplementary material available at 10.1007/s11033-026-11641-0.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], NR5A2 (nuclear receptor subfamily 5 group A member 2) [NCBI Gene 2494], SAA1 (serum amyloid A1) [NCBI Gene 6288], LDLR (low density lipoprotein receptor) [NCBI Gene 3949], APOA1 (apolipoprotein A1) [NCBI Gene 335], ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19], PON1 (paraoxonase 1) [NCBI Gene 5444], PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738]
- **Chemicals:** phorbol-12-myristate-13-acetate (PubChem CID 4792)

## Full-text entities

- **Genes:** NR5A2 (nuclear receptor subfamily 5 group A member 2) [NCBI Gene 2494] {aka B1F, B1F2, CPF, FTF, FTZ-F1, FTZ-F1beta}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MDH1 (malate dehydrogenase 1) [NCBI Gene 4190] {aka DEE88, EIEE88, HEL-S-32, KAR, MDH-s, MDHA}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, TBP (TATA-box binding protein) [NCBI Gene 6908] {aka GTF2D, GTF2D1, HDL4, SCA17, TBP1, TFIID}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PON1 (paraoxonase 1) [NCBI Gene 5444] {aka ESA, MVCD5, PON}, ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, LCAT (lecithin-cholesterol acyltransferase) [NCBI Gene 3931], HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, SAA [NCBI Gene 6287], APOC3 (apolipoprotein C3) [NCBI Gene 345] {aka APOCIII, Apo-C3, ApoC-3}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}
- **Diseases:** cardiovascular complications (MESH:D002318), cytotoxicity (MESH:D064420), arthritis (MESH:D001168), atherosclerosis (MESH:D050197), sepsis (MESH:D018805), CIDs (MESH:D002908), hepatic alterations (MESH:D056486), acute and chronic inflammation (MESH:D007249), monocytic leukemia (MESH:D007951), CM (MESH:D010033), piHDL (MESH:D013631)
- **Chemicals:** MTT (MESH:C070243), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), DMEM HG (-), HEPES (MESH:D006531), penicillin (MESH:D010406), PVDF (MESH:C024865), PBS (MESH:D007854), DAPI (MESH:C007293), DMSO (MESH:D004121), agarose (MESH:D012685), Lipid (MESH:D008055), LPS (MESH:D008070), PMA (MESH:D013755), streptomycin (MESH:D013307), Triton X-100 (MESH:D017830), TAG (MESH:D014280), formazan (MESH:D005562), cholesterol (MESH:D002784), ethanol (MESH:D000431), tetrazolium (MESH:D013778), NaF (MESH:D012969), FFAs (MESH:D005230)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966263/full.md

---
Source: https://tomesphere.com/paper/PMC12966263